文献速递头颈部肿瘤放疗放疗物理与技术

头颈癌计划剂量与实际递送剂量差异及其对正常组织并发症概率与治疗适应的影响

Differences between planned and delivered dose for head and neck cancer, and their consequences for normal tissue complication probability and treatment adaptation.
PubMed 文献 · Radiother Oncol · 2019-08-17

本研究对52例头颈癌患者累积每日剂量以估计实际递送剂量,分析其与计划剂量在CTV和9个OAR的差异,并计算6个月时口腔干燥、吞咽困难、腮腺功能异常和管饲依赖的ΔNTCP。ΔNTCP>5%被视为需要ART,用第10和第15分次累积剂量的ΔNTCP预测ART患者的PPV分别为0.86和0.75,优于临床判断的0.38。

要点

  • 头颈癌计划与实际递送剂量存在差异,可导致ΔNTCP>5%需ART。
  • 基于第10分次累积剂量的ΔNTCP预测ART的PPV为0.86,优于临床判断。
  • ΔNTCP>5%作为ART选择标准时,第10分次阴性预测值为0.93。

核心结论

  • 基于第10分次计划与实际递送剂量差异计算的NTCP可准确识别需ART的头颈癌患者,优于临床判断。

研究设计与样本

  • 对52例头颈癌患者累积每日剂量估计实际递送剂量,分析其与计划剂量在CTV和9个OAR的差异。
  • 计算6个月时口腔干燥、吞咽困难、腮腺功能异常和管饲依赖的ΔNTCP,ΔNTCP>5%视为需ART。
  • 计算临床判断及第10、15分次ΔNTCP识别ART患者的阳性预测值(PPV)。

主要发现

  • ΔNTCP>5%在吞咽困难中出现5次,其他毒性各出现2次。
  • 9例ΔNTCP>5%患者中仅5例临床接受ART,而52例中13例实际接受ART(PPV=0.38)。
  • 第10和15分次累积剂量ΔNTCP的PPV分别为0.86和0.75(ΔNTCP截断值5%)。
  • 该截断值下,第10和15分次ΔNTCP方法的阴性预测值分别为0.93和0.93,临床判断为0.90。

关键数值与推荐

  • ART必要性判定标准:ΔNTCP>5%。
  • ART分配ΔNTCP截断值:5%。
  • 第10分次ΔNTCP方法PPV=0.86,第15分次PPV=0.75,临床判断PPV=0.38。
  • 第10和15分次ΔNTCP方法阴性预测值均为0.93,临床判断为0.90。

临床怎么用

  • 可基于第10分次累积剂量计算的ΔNTCP客观筛选需ART的头颈癌患者。
  • ΔNTCP>5%可作为ART选择的参考阈值,但需结合临床实际。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Anatomical changes induce differences between planned and delivered dose. Adaptive radiotherapy (ART) may reduce these differences but the optimal implementation is insufficiently clear. The aims of this study were to quantify the difference between planned and delivered dose in HNC patients, assess the consequential difference in normal tissue complication probability (ΔNTCP) and to explore the value of ΔNTCP as an objective selection strategy for ART. MATERIALS AND METHODS: For 52 patients, daily doses were accumulated to estimate the delivered dose. The difference from planned dose was analyzed for CTVs and 9 organs-at-risk (OAR). ΔNTCP was calculated for xerostomia, dysphagia, parotid gland dysfunction and tube feeding dependency at 6 months. ART was deemed necessary if ΔNTCP was >5%. The positive predicted value (PPV) was calculated for identification of ART-patients by clinical judgement, and ΔNTCP at fraction 10 and 15. RESULTS: ΔNTCP >5% was seen five times for dysphagia and twice for the other toxicities. Only 5/9 patients with any ΔNTCP >5% clinically received ART, although ART had been done for 13/52 patients (PPV: 0.38). PPV was 0.86 and 0.75 for accumulated dose at fraction 10 and 15, respectively, using a ΔNTCP cut-off for the allocation of ART of 5%. Using other ΔNTCP cut-offs did not substantially improve PPV. With this cut-off the negative predictive value was 0.93 for ΔNTCP method of fraction 10 and fraction 15, and 0.90 for clinical judgement. CONCLUSION: To identify patients accurately for ART, NTCP calculations based on the dose differences between planned and delivered dose at fraction 10 are superior to clinical judgement.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Heukelom J, Kantor ME, Mohamed ASR, et al. Differences between planned and delivered dose for head and neck cancer, and their consequences for normal tissue complication probability and treatment adaptation. Radiother Oncol. 2019. PMID: 31431381. doi:10.1016/j.radonc.2019.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。